Posted on November 9, 2017 by Sitemaster
Just over a year ago, we reported on a paper by Hearn et al. that had shown that a specific inherited mutation in the HSD3B1 gene seemed to be associated with a more aggressive form of prostate cancer that was less responsive to treatment with androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 1245C, allele, CYP17A1, HSD3B1, inhibition, Treatment, variant | 2 Comments »
Posted on October 17, 2017 by Sitemaster
Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: 3βHSD1, ADT, genetic, germline, HSD3B1, profile, response, Treatment | Leave a comment »